MX2015012063A - Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. - Google Patents

Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.

Info

Publication number
MX2015012063A
MX2015012063A MX2015012063A MX2015012063A MX2015012063A MX 2015012063 A MX2015012063 A MX 2015012063A MX 2015012063 A MX2015012063 A MX 2015012063A MX 2015012063 A MX2015012063 A MX 2015012063A MX 2015012063 A MX2015012063 A MX 2015012063A
Authority
MX
Mexico
Prior art keywords
cancer
oligonucletotides
antisense
treatment
stem cells
Prior art date
Application number
MX2015012063A
Other languages
English (en)
Other versions
MX359337B (es
Inventor
Veronica A Burzio Menendez
Jaime E Villegas Olavarria
Luis O Burzio Eriz
Original Assignee
Andes Biotechnologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andes Biotechnologies S A filed Critical Andes Biotechnologies S A
Publication of MX2015012063A publication Critical patent/MX2015012063A/es
Publication of MX359337B publication Critical patent/MX359337B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención, proporciona oligonucleótidos complementarios a un ARN quimérico mitocondrial no codificante como composiciones y kits que comprenden el mismo, y su uso en el tratamiento y prevención de la metástasis o reincidencia de un cáncer, en un individuo previamente tratado para el cáncer con una terapia. La invención también proporciona oligonucleótidos complementarios a un ARN quimérico mitocondrial no codificante, asi como composiciones y kits que comprende los mismos y su uso en el tratamiento de un cáncer refractario (o resistente) (por ejemplo un cáncer HPV asociado refractario (o resistente) ).
MX2015012063A 2013-03-14 2014-03-14 Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer. MX359337B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361785269P 2013-03-14 2013-03-14
US201361790072P 2013-03-15 2013-03-15
US201461937438P 2014-02-07 2014-02-07
PCT/US2014/029606 WO2014153209A1 (en) 2013-03-14 2014-03-14 Antisense oligonucletotides for treatment of cancer stem cells

Publications (2)

Publication Number Publication Date
MX2015012063A true MX2015012063A (es) 2016-04-06
MX359337B MX359337B (es) 2018-07-09

Family

ID=51581450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012063A MX359337B (es) 2013-03-14 2014-03-14 Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.

Country Status (14)

Country Link
US (3) US9862944B2 (es)
EP (1) EP2970970B1 (es)
JP (1) JP6313419B2 (es)
CN (2) CN115518073A (es)
BR (1) BR112015022308A8 (es)
CA (1) CA2906198C (es)
CL (1) CL2015002612A1 (es)
DK (1) DK2970970T3 (es)
ES (1) ES2708650T3 (es)
HK (1) HK1220482A1 (es)
HU (1) HUE042738T2 (es)
MX (1) MX359337B (es)
PL (1) PL2970970T3 (es)
WO (1) WO2014153209A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359337B (es) 2013-03-14 2018-07-09 Andes Biotechnologies Global Inc Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
JP2016519083A (ja) 2013-03-14 2016-06-30 アンデス バイオテクノロジーズ ソシエダード アノニマＡｎｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｓ．Ａ． 多発性骨髄腫を検出および処置するための方法
KR102145176B1 (ko) * 2017-11-27 2020-08-18 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
US20220177852A1 (en) * 2019-04-11 2022-06-09 Genex Health CO., LTD. Method for culturing primary cells of gastric cancer and gallbladder and bile duct cancer, and supporting reagents
CN113893261B (zh) * 2021-06-22 2023-01-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） circITGB6-ASO与铂类化疗药物联合使用在制备治疗卵巢癌的药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US5721218A (en) 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
IL99066A (en) 1990-08-03 1996-01-31 Sterling Winthrop Inc Nuclease-resistant compounds containing oligonucleotide sequences having either or both of the ends, and preparations containing them
JPH06505704A (ja) 1990-09-20 1994-06-30 ギリアド　サイエンシズ，インコーポレイテッド 改変ヌクレオシド間結合
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
DE637965T1 (de) 1991-11-26 1995-12-14 Gilead Sciences Inc Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen.
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
AU6412794A (en) 1993-03-31 1994-10-24 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5646269A (en) 1994-04-28 1997-07-08 Gilead Sciences, Inc. Method for oligonucleotide analog synthesis
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
HUE032575T2 (en) 2003-05-21 2017-10-30 Andes Biotechnologies S A Compounds and Oligonucleotides for Diagnosis and Treatment of Cancer and Cancer Prevention
CN101291741B (zh) 2005-10-20 2011-11-16 株式会社德山 涂敷液的混入空气的除去方法及其除去装置
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
WO2007134014A2 (en) 2006-05-05 2007-11-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gcgr
WO2009026576A1 (en) * 2007-08-23 2009-02-26 Keren Pharmaceuticals Targeting rna with external guide sequences
AU2008327541B2 (en) 2007-11-20 2014-02-27 Hopitaux Universitaires De Geneve Methods for identifying, purifying and enriching immature or stem cancer-initiating cells from tumors and use thereof
ES2646097T3 (es) * 2009-08-27 2017-12-12 Idera Pharmaceuticals, Inc. Composición para inhibir la expresión de genes y sus usos
JP2016519083A (ja) 2013-03-14 2016-06-30 アンデス バイオテクノロジーズ ソシエダード アノニマＡｎｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ Ｓ．Ａ． 多発性骨髄腫を検出および処置するための方法
MX359337B (es) 2013-03-14 2018-07-09 Andes Biotechnologies Global Inc Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.

Also Published As

Publication number Publication date
CA2906198C (en) 2022-11-29
EP2970970A4 (en) 2016-10-19
US10457943B2 (en) 2019-10-29
WO2014153209A1 (en) 2014-09-25
HUE042738T2 (hu) 2019-07-29
PL2970970T3 (pl) 2019-06-28
CL2015002612A1 (es) 2016-08-26
JP6313419B2 (ja) 2018-04-18
HK1220482A1 (zh) 2017-05-05
JP2016519084A (ja) 2016-06-30
US20200239885A1 (en) 2020-07-30
ES2708650T3 (es) 2019-04-10
EP2970970B1 (en) 2018-12-12
US11319535B2 (en) 2022-05-03
US9862944B2 (en) 2018-01-09
CN115518073A (zh) 2022-12-27
CN105229150A (zh) 2016-01-06
CA2906198A1 (en) 2014-09-25
BR112015022308A8 (pt) 2018-01-23
MX359337B (es) 2018-07-09
DK2970970T3 (en) 2019-02-11
BR112015022308A2 (pt) 2017-10-10
US20180171335A1 (en) 2018-06-21
WO2014153209A8 (en) 2015-02-26
EP2970970A1 (en) 2016-01-20
US20160138015A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
PH12018502570A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX363846B (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MY178390A (en) Inhibitors of iap
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
NZ744845A (en) Cancer treatment
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA201992441A1 (ru) Способы лечения с использованием аденовируса
GB201207056D0 (en) Wound treatment

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ANDES BIOTECHNOLOGIES GLOBAL, INC.

HC Change of company name or juridical status

Owner name: ARRIS ENTERPRISES, LLC

FG Grant or registration